FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4205149176> ?p ?o ?g. }

• W4205149176 endingPage "341" @default.
• W4205149176 startingPage "332" @default.
• W4205149176 abstract "<h2>Summary</h2><h3>Background</h3> Endoscopic balloon dilation (EBD) is the established endoscopic treatment for short strictures in Crohn's disease. Fully covered self-expandable metal stents (FCSEMS) have been used for endoscopic treatment of patients for whom EBD was unsuccessful. We aimed to determine the efficacy and safety of the two endoscopic treatments in patients with Crohn's disease with stenosis and compare the mean cost of both treatments. <h3>Methods</h3> This multicentre, open-label, randomised trial was done in 19 tertiary and secondary hospitals in Spain. Patients with Crohn's disease with obstructive symptoms and predominantly fibrotic strictures of less than 10 cm in length were eligible for inclusion. We excluded patients with stenosis treated with SEMS or EBD in the previous year and stenosis not accessible to a colonoscope. Patients were randomly assigned (1:1) to receive either EBD (EBD group) or FCSEMS (FCSEMS group) using a digital en-block randomisation system (block size of four). In the EBD group, dilation was done with a CRE Boston Scientific (Marlborough, MA, USA) pneumatic balloon with the diameter set at the discretion of the endoscopist; a maximum of two sessions of dilation were allowed with a minimum interval of 15–30 days between them. In the FCSEMS group, a 20 mm diameter Taewoong (Gimpo-si, South Korea) fully covered metal stent was placed; stent length was set at the discretion of the endoscopist. The primary outcome was to assess the efficacy of the endoscopic treatment, defined by the proportion of patients free of a new therapeutic intervention (EBD, FCSEMS, or surgery) due to symptomatic recurrence at 1 year of follow-up. Patients were analysed according to the intention-to-treat principle. Adverse events were recorded for all the patients; events were considered associated to be with the procedure when a causal association was possible, probable, or definite. This trial is registered with ClinicalTrials.gov, NCT02395354. <h3>Findings</h3> From Aug 28, 2013, to Oct 9, 2017, we assessed the eligibility of 99 patients, of whom 19 (19%) patients were excluded. Thus, 80 (81%) patients were randomly assigned to treatment: 39 (49%) patients to the FCSEMS group and 41 (51%) patients to the EBD group. 33 (80%) of 41 patients in the EBD group and 20 (51%) of 39 patients in the FCSEMS group were free of a new therapeutic intervention at 1 year (odds ratio [OR] 3·9 [95% CI 1·4–10·6]; p=0·0061). Two (3%) of 80 patients had severe adverse events (one [2%] patient in the EBD group and one [3%] patient in the FCSEMS group); both patients had perforations. <h3>Interpretation</h3> EBD is more effective than FCSEMS for Crohn's disease strictures, with a good safety profile for both treatments. <h3>Funding</h3> Spanish National Institute of Health, Foundation of Spanish Society of Digestive Endoscopy, Catalan Society of Gastroenterology, and Taweoong." @default.
• W4205149176 created "2022-01-25" @default.
• W4205149176 creator A5002961219 @default.
• W4205149176 creator A5003033228 @default.
• W4205149176 creator A5008463240 @default.
• W4205149176 creator A5010003627 @default.
• W4205149176 creator A5012338853 @default.
• W4205149176 creator A5014945298 @default.
• W4205149176 creator A5020176883 @default.
• W4205149176 creator A5020958920 @default.
• W4205149176 creator A5028698159 @default.
• W4205149176 creator A5029760349 @default.
• W4205149176 creator A5030043156 @default.
• W4205149176 creator A5033282443 @default.
• W4205149176 creator A5039894059 @default.
• W4205149176 creator A5043396998 @default.
• W4205149176 creator A5046814332 @default.
• W4205149176 creator A5048774215 @default.
• W4205149176 creator A5049266696 @default.
• W4205149176 creator A5051656130 @default.
• W4205149176 creator A5065754671 @default.
• W4205149176 creator A5066541527 @default.
• W4205149176 creator A5069146494 @default.
• W4205149176 creator A5078953154 @default.
• W4205149176 creator A5079654463 @default.
• W4205149176 creator A5084079496 @default.
• W4205149176 creator A5090246561 @default.
• W4205149176 date "2022-04-01" @default.
• W4205149176 modified "2023-10-18" @default.
• W4205149176 title "Self-expandable metal stents versus endoscopic balloon dilation for the treatment of strictures in Crohn's disease (ProtDilat study): an open-label, multicentre, randomised trial" @default.
• W4205149176 cites W1736289269 @default.
• W4205149176 cites W1966310006 @default.
• W4205149176 cites W1969654508 @default.
• W4205149176 cites W1990002544 @default.
• W4205149176 cites W2009256676 @default.
• W4205149176 cites W2043760494 @default.
• W4205149176 cites W2083759302 @default.
• W4205149176 cites W2088826436 @default.
• W4205149176 cites W2093467790 @default.
• W4205149176 cites W2130345070 @default.
• W4205149176 cites W2147159376 @default.
• W4205149176 cites W2161015371 @default.
• W4205149176 cites W2162184641 @default.
• W4205149176 cites W2299059064 @default.
• W4205149176 cites W2302300381 @default.
• W4205149176 cites W2327068557 @default.
• W4205149176 cites W2334564081 @default.
• W4205149176 cites W2345011866 @default.
• W4205149176 cites W2529401211 @default.
• W4205149176 cites W2563460590 @default.
• W4205149176 cites W2791213050 @default.
• W4205149176 cites W2800860080 @default.
• W4205149176 cites W2809196018 @default.
• W4205149176 cites W2898584930 @default.
• W4205149176 cites W2913627078 @default.
• W4205149176 cites W2947679768 @default.
• W4205149176 cites W2973512053 @default.
• W4205149176 cites W2984128211 @default.
• W4205149176 cites W3006975688 @default.
• W4205149176 cites W3045708145 @default.
• W4205149176 cites W3094275748 @default.
• W4205149176 doi "https://doi.org/10.1016/s2468-1253(21)00386-1" @default.
• W4205149176 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35065738" @default.
• W4205149176 hasPublicationYear "2022" @default.
• W4205149176 type Work @default.
• W4205149176 citedByCount "20" @default.
• W4205149176 countsByYear W42051491762022 @default.
• W4205149176 countsByYear W42051491762023 @default.
• W4205149176 crossrefType "journal-article" @default.
• W4205149176 hasAuthorship W4205149176A5002961219 @default.
• W4205149176 hasAuthorship W4205149176A5003033228 @default.
• W4205149176 hasAuthorship W4205149176A5008463240 @default.
• W4205149176 hasAuthorship W4205149176A5010003627 @default.
• W4205149176 hasAuthorship W4205149176A5012338853 @default.
• W4205149176 hasAuthorship W4205149176A5014945298 @default.
• W4205149176 hasAuthorship W4205149176A5020176883 @default.
• W4205149176 hasAuthorship W4205149176A5020958920 @default.
• W4205149176 hasAuthorship W4205149176A5028698159 @default.
• W4205149176 hasAuthorship W4205149176A5029760349 @default.
• W4205149176 hasAuthorship W4205149176A5030043156 @default.
• W4205149176 hasAuthorship W4205149176A5033282443 @default.
• W4205149176 hasAuthorship W4205149176A5039894059 @default.
• W4205149176 hasAuthorship W4205149176A5043396998 @default.
• W4205149176 hasAuthorship W4205149176A5046814332 @default.
• W4205149176 hasAuthorship W4205149176A5048774215 @default.
• W4205149176 hasAuthorship W4205149176A5049266696 @default.
• W4205149176 hasAuthorship W4205149176A5051656130 @default.
• W4205149176 hasAuthorship W4205149176A5065754671 @default.
• W4205149176 hasAuthorship W4205149176A5066541527 @default.
• W4205149176 hasAuthorship W4205149176A5069146494 @default.
• W4205149176 hasAuthorship W4205149176A5078953154 @default.
• W4205149176 hasAuthorship W4205149176A5079654463 @default.
• W4205149176 hasAuthorship W4205149176A5084079496 @default.
• W4205149176 hasAuthorship W4205149176A5090246561 @default.
• W4205149176 hasConcept C126322002 @default.
• W4205149176 hasConcept C139059822 @default.
• W4205149176 hasConcept C141071460 @default.
• W4205149176 hasConcept C168563851 @default.

• next